Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 16, 2026

Starbucks Corporation Announces Early Results and Upsizing of its Tender Offers for Eight Series of Notes

View original at finance.yahoo.com
“4.500% Senior Notes due 2028 [CUSIP 855244BN8] Aggregate Principal Amount Outstanding: $750,000,000”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Because the aggregate purchase price of tendered Notes exceeds the Aggregate Cap and Maximum Amounts, Starbucks does not expect to accept any further tenders of Notes

    60% confidence

  • Starbucks increased the Aggregate Cap for all Notes to $1.3 billion, the Pool 1 Maximum Amount to $600 million, and the Pool 2 Maximum Amount to $700 million

    60% confidence

  • $2,598,857,000 aggregate principal amount of the Notes were validly tendered prior to or at 5:00 p.m. Eastern Time on May 15, 2026 and not validly withdrawn

    60% confidence

  • The 4.500% Senior Notes due 2048 are subject to an aggregate principal amount sublimit of $200,000,000

    60% confidence

  • Except as described in the May 16 press release, the terms and conditions of the Tender Offers set forth in the Offer to Purchase remain unchanged

    60% confidence

Data points we hold from this source

Starbucks Corporation · principal tendered2598857000 USD
Starbucks Corporation · debt5000000000 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Starbucks Corporation Announces Early Results and Upsizing of its Tender Offers for Eight Series of Notes — Source | Via News | Finance Via News